The report covers emerging Vitiligo drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Vitiligo treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vitiligo: An Overview
Vitiligo is a common acquired skin disorder that results from the loss of melanocytes from the epidermis and clinically manifests as well-demarcated white patches on the body. The condition is usually associated with a few autoimmune disorders, with thyroid abnormalities being the commonest one.
In 2011, an international consensus classified vitiligo into two major forms: nonsegmental vitiligo (NSV) and segmental vitiligo (SV). The term vitiligo was defined to designate all forms of NSV (including acrofacial, mucosal, generalized, universal, mixed, and rare variants). Distinguishing SV from other types of vitiligo was one of the most important decisions of the consensus, primarily because of its prognostic implications.
The cause is unknown but might involve genetic factors, autoimmunity, neurologic factors, toxic metabolites, and lack of melanocyte growth factors. There are different clinical variants of vitiligo which are Trichrome, Marginal inflammatory, and Quadrichrome vitiligo.
Vitiligo Market Key Facts
-
Vitiligo develops at all ages and affects both sexes equally. Despite the same prevalence ratio of 1:1 in males and females, the ratio of treatment requests is 1:2.
-
US population-based prevalence estimate of overall (diagnosed and undiagnosed combined) vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020).
-
The 12-month prevalence of vitiligo in the 7MM was assessed to be 8.1 M in 2021, which is expected to increase during the study period (2019–2032).
-
Although the prevalence of vitiligo was expected to decrease in Japan, the diagnosed patient pool of vitiligo was 0.4 M in 2021.
-
The total number of diagnosed cases of vitiligo in the 7MM was 4.5 M in 2021.
-
In 2021, the US had 1.2 M cases of segmental and 3.4 M cases of nonsegmental vitiligo, which are expected to increase significantly during the study period (2019–2032).
-
Among EU4 and the UK, Germany had the highest prevalent population of vitiligo, which was about 0.7 M, followed by France, and the United Kingdom, while Spain had the lowest prevalence in 2021.
-
As per DelveInsight, the Vitiligo Market is anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases of Vitiligo in 7MM and the expected launch of the pipeline therapies.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Vitiligo pipeline therapies. It also thoroughly assesses the Vitiligo market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Vitiligo drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Vitiligo Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Vitiligo epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Vitiligo epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Vitiligo Epidemiology, Segmented as –
-
Prevalent Cases of Vitiligo [2019–2032]
-
Age-Specific Prevalent Cases of Vitiligo [2019–2032]
-
Prevalence of Vitiligo based on Subtype [2019–2032]
-
Diagnosed and Treatable Cases of Vitiligo [2019–2032]
-
Prevalent Cases of Vitiligo based on Gender [2019–2032]
Vitiligo Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Vitiligo market or expected to be launched during the study period. The analysis covers the Vitiligo market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Vitiligo drugs based on their sale and market share.
The report also covers the Vitiligo pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Vitiligo companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Vitiligo Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/vitiligo-market
Vitiligo Therapeutics Analysis
Several major pharma and biotech giants are actively developing therapies for Vitiligo. Currently, Incyte Corporation is leading the therapeutics market with its Vitiligo drug candidates in the most advanced stage of clinical development.
On March 18, 2023, Incyte (Nasdaq: INCY) announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented today in a late-breaking oral presentation (Session: S042 – Late-Breaking Research: Session 2) at the 2023 American Academy of Dermatology (AAD) Annual Meeting, held from March 17-21 in New Orleans.
On January 09, 2023, VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) announced that the first vitiligo patient has been dosed in a Phase 1a/b clinical trial of VYN201. VYN201 is a locally administered, small molecule, pan-bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases. The clinical trial is a first-in-human study designed to generate safety and pharmacokinetic data in healthy volunteers (Phase 1a) as well as provide early clinical proof-of-concept data in vitiligo patients (Phase 1b).
Vitiligo Companies Actively Working in the Therapeutics Market Include
-
Incyte Corporation
-
Amgen
-
Boston Pharmaceuticals
-
Arcutis Biotherapeutics
-
Pfizer
-
Dermavant Sciences
-
Clinuvel Pharmaceuticals
-
Celgene
-
TWi Biotechnology
-
AXIM Biotechnologies
-
Arrien Pharmaceuticals
And many others
Emerging and Marketed Vitiligo Therapies Covered in the Report Include:
-
Ruxolitinib: Incyte Corporation
-
AMG-714: Amgen
-
ATI-1777: Aclaris Therapeutics
-
TT-01: Temprian Therapeutics
-
1BNZ-1: Bioniz Therapeutics
-
Phimelanotide Clinuvel Pharmaceuticals
-
AC-1101: TWi Biotechnology
-
PF-06651600: Pfizer
-
Cerdulatinib: Dermavant Sciences
-
SHR0302 ointment: Reistone Biopharma Company Limited
And many more
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/vitiligo-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Vitiligo Competitive Intelligence Analysis
4. Vitiligo Market Overview at a Glance
5. Vitiligo Disease Background and Overview
6. Vitiligo Patient Journey
7. Vitiligo Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Vitiligo Treatment Algorithm, Current Treatment, and Medical Practices
9. Vitiligo Unmet Needs
10. Key Endpoints of Vitiligo Treatment
11. Vitiligo Marketed Therapies
12. Vitiligo Emerging Drugs and Latest Therapeutic Advances
13. Vitiligo Seven Major Market Analysis
14. Attribute Analysis
15. Vitiligo Market Outlook (In US, EU5, and Japan)
16. Vitiligo Companies Active in the Market
17. Vitiligo Access and Reimbursement Overview
18. KOL Views on the Vitiligo Market
19. Vitiligo Market Drivers
20. Vitiligo Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/vitiligo-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Desmoplastic Small Round Cell Tumors (DSRCTS) Market
“Desmoplastic Small Round Cell Tumors (DSRCTS) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Desmoplastic Small Round Cell Tumors market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the DSRCTS market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/